AB Science: positive phase 2 data in Covid-19

(CercleFinance.com) - AB Science reports positive results for a phase 2 study evaluating the safety and efficacy of its masitinib combined with isoquercetin in hospitalized patients with moderate to severe Covid-19.


The study showed an odds ratio of 2.4 in favor of the treatment arm after 15 days of treatment, higher than the odds ratio of 2.2 initially assumed, with a p-value of 0.038 simulated with 200 patients and a p-value of 0.072 detected with the 95 patients enrolled.

With this result, masitinib can be considered a drug of choice for evaluation in the context of a future pandemic", comments Olivier Hermine, Chairman of AB Science's Scientific Committee and member of the French Academy of Sciences.

Copyright (c) 2024 CercleFinance.com. All rights reserved.